Effectiveness and safety of Danmu extract syrup for acute upper respiratory tract infection in children: A real‐world, prospective cohort study. Issue 1 (13th April 2022)

• Record Type: Journal Article
• Authors: Zeng, Linan; Li, Hailong; Zhang, Chuan; Kang, Deying; Liu, Guanjian; Li, Xihong; Chen, Lina; Zeng, Min; Huang, Liang; Xu, Peipei; Feng, Shiyin; Yu, Qin; Liu, Hanmin; Zhang, Lingli
• Is Part Of: Journal of evidence-based medicine. Volume 15:Issue 1(2022)
• Page Start: 19
• Page End: 29
• Publication Date: 2022-04-13
• Subjects: acute upper respiratory tract infection -- cohort study -- Danmu extract syrup -- real‐world study -- traditional Chinese medicine; Evidence-based medicine -- Periodicals; Systematic reviews (Medical research) -- Periodicals; 616.005
• DOI: 10.1111/jebm.12464
• Languages: English
• ISSNs: 1756-5383

Abstract

Abstract: Aim: To evaluate the effectiveness and safety of Danmu Extract Syrup for the treatment of acute upper respiratory tract infection (AURI) in children. Methods: In this prospective cohort study, we enrolled children with AURI in the pediatric outpatient department and emergency department of West China Second Hospital. According to the treatment, they were divided into two groups: Danmu Extract Syrup Group (Danmu Group) and Xiaoer Chiqiao Granule Group (Chiqiao Group). The primary outcome was time to symptom remission, and the secondary outcomes were defervescence time, relief time, admission rate, and adherence. We used restricted mean survival time (RMST) to quantify the treatment effects and test noninferiority for primary outcome. Propensity score matching (PSM) was used to adjust confounding. Subgroup analysis and sensitivity analysis were used to verify the robustness of results. Results: We enrolled 1036 children with AURI, including 516 in Danmu Group and 520 in Chiqiao Group. After PSM, no significant difference was observed in the baseline characteristics of the two groups. The primary results showed that the RMST difference was –3 h (95% CI: –15.1 to 9.1) and the upper limit of the 95% CI was less than the noninferiority margin of 11 h. There was no statistical difference in the secondary outcomes except for defervescence between the two groups. The results of safety analysis showed that the incidence of adverse events occurred is 4.1% in Danmu Group, which was lower than the incidence of Chiqiao Group (6.9%). Conclusion: This study indicated that Danmu extract syrup is noninferiority to Chiqiao Granule for AURI in children.